口服司美格鲁肽单药治疗与安慰剂在以中国人群为主的2型糖尿病患者中的疗效与安全性(PIONEER 11):一项双盲、IIIa期、随机试验
PIONEER 11是一项双盲、随机、IIIa期试验,在52个中心纳入521例仅靠饮食运动控制不佳的2型糖尿病患者,随机接受口服司美格鲁肽3、7、14 mg或安慰剂治疗26周。口服司美格鲁肽各剂量均显著降低HbA1c,7 mg和14 mg剂量显著降低体重,安全性与全球PIONEER试验一致。
要点
- 口服司美格鲁肽3、7、14 mg较安慰剂显著降低HbA1c,估计治疗差异分别为-11、-16、-17 mmol/mol。
- 口服司美格鲁肽7 mg和14 mg较安慰剂显著降低体重,估计治疗差异分别为-1.2 kg和-2.0 kg。
- 口服司美格鲁肽3 mg降低体重与安慰剂无显著差异,估计治疗差异-0.0 kg(95%CI -0.9, 0.8)。
核心结论
- 在以中国人群为主的饮食运动控制不佳的2型糖尿病患者中,口服司美格鲁肽各剂量较安慰剂显著降低HbA1c,7 mg和14 mg剂量较安慰剂显著降低体重。
- 口服司美格鲁肽总体耐受性良好,安全性特征与全球PIONEER试验中观察到的一致。
研究设计与样本
- PIONEER 11为双盲、随机、IIIa期试验,在中国地区(中国大陆和台湾)、匈牙利、塞尔维亚和乌克兰的52个中心开展。
- 纳入年龄≥18岁(台湾≥20岁)、诊断为2型糖尿病且HbA1c 53-86 mmol/mol(7.0-10.0%)、未接受任何降糖药物治疗的参与者。
- 经过4周仅饮食和运动的导入期后,符合随机化标准的参与者按1:1:1:1随机接受每日一次口服司美格鲁肽3 mg、7 mg、14 mg或安慰剂治疗26周(较高剂量采用4周剂量递增方案),随机化按来自中国地区或其他地区分层。
- 共筛查774例参与者,随机化521例:口服司美格鲁肽3 mg(n=130)、7 mg(n=130)、14 mg(n=130)或安慰剂(n=131)。
- 多数参与者为男性(63.7%),平均年龄52岁;基线平均HbA1c为63 mmol/mol(8.0%),平均体重为79.6 kg。
主要发现
- 第26周时,口服司美格鲁肽各剂量较安慰剂显著降低HbA1c(所有剂量p<0.001);3 mg、7 mg和14 mg较安慰剂的估计治疗差异(95%CI)分别为-11(-13, -9)mmol/mol、-16(-18, -13)mmol/mol和-17(-19, -15)mmol/mol。
- 对应的百分数点估计治疗差异(95%CI)较安慰剂分别为-1.0(-1.2, -0.8)、-1.4(-1.6, -1.2)和-1.5(-1.8, -1.3)。
- 第26周时,口服司美格鲁肽7 mg和14 mg较安慰剂显著降低体重,估计治疗差异(95%CI)分别为-1.2 kg(-2.0 kg, -0.4 kg;p<0.01)和-2.0 kg(-2.8 kg, -1.2 kg;p<0.001);3 mg较安慰剂无显著差异,估计治疗差异(95%CI)为-0.0 kg(-0.9 kg, 0.8 kg;not significant)。
- 中国亚人群(占总体人群74.9%)中观察到相似的HbA1c和体重降低。
- 口服司美格鲁肽(所有剂量)组不良事件发生率为65.4%至72.3%,安慰剂组为57.3%;大多数不良事件为轻至中度,严重不良事件较少;最常见的不良事件为胃肠道相关,且司美格鲁肽(所有剂量)组较安慰剂组更频繁。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: The aim of this study was to evaluate the efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes insufficiently controlled with diet and exercise alone. METHODS: The Peptide Innovation for Early Diabetes Treatment (PIONEER) 11 trial was a double-blind, randomised, Phase IIIa trial conducted across 52 sites in the China region (mainland China and Taiwan), Hungary, Serbia and Ukraine. Eligible participants were ≥18 years (≥20 years in Taiwan), had a diagnosis of type 2 diabetes with HbA1c 53-86 mmol/mol (7.0-10.0%) and were not receiving any glucose-lowering drugs. After a 4-week run-in period in which participants were treated with diet and exercise alone, those who fulfilled the randomisation criteria were randomised (1:1:1:1) using a web-based randomisation system to receive once-daily oral semaglutide 3 mg, 7 mg or 14 mg or placebo for 26 weeks (using a 4-week dose-escalation regimen for the higher doses). Randomisation was stratified according to whether participants were from the China region or elsewhere. The primary and confirmatory secondary endpoints were change from baseline to week 26 in HbA1c and body weight (kg), respectively. Safety was assessed in all participants exposed to at least one dose of the trial product. RESULTS: Between October 2019 and October 2021, a total of 774 participants were screened and 521 participants were randomised to oral semaglutide 3 mg (n=130), 7 mg (n=130), 14 mg (n=130) or placebo (n=131); most participants (92.5%, n=482) completed the trial, with 39 participants prematurely discontinuing treatment. The number of participants contributing to the trial analyses was based on the total number of participants who were randomised at the beginning of the trial. The majority of participants were male (63.7%), and the mean age of participants was 52 years. At baseline, mean HbA1c and body weight were 63 mmol/mol (8.0%) and 79.6 kg, respectively. Oral semaglutide resulted in significantly greater reductions in HbA1c than placebo at week 26 (p<0.001 for all doses). The estimated treatment differences (ETDs [95% CIs]) for oral semaglutide 3 mg, 7 mg and 14 mg vs placebo were -11 (-13, -9) mmol/mol, -16 (-18, -13) mmol/mol and -17 (-19, -15) mmol/mol, respectively. The corresponding ETDs in percentage points (95% CI) vs placebo were -1.0 (-1.2, -0.8), -1.4 (-1.6, -1.2) and -1.5 (-1.8, -1.3), respectively. Significantly greater reductions in body weight were also observed for oral semaglutide 7 mg and 14 mg than for placebo at week 26 (ETD [95% CI] -1.2 kg [-2.0 kg, -0.4 kg; p<0.01] and -2.0 kg [-2.8 kg, -1.2 kg; p<0.001], respectively), but not for oral semaglutide 3 mg (ETD [95% CI] -0.0 kg [-0.9 kg, 0.8 kg; not significant]). Similar reductions in HbA1c and body weight were observed in the Chinese subpopulation, which represented 74.9% of participants in the overall population. Adverse events (AEs) occurred in between 65.4% and 72.3% of participants receiving oral semaglutide (for all doses) and 57.3% of participants with placebo. Most AEs were mild to moderate in severity, with few serious AEs reported; the most commonly reported AEs were gastrointestinal-related and were more frequent with semaglutide (all doses) than with placebo. The proportion of AEs was slightly higher in the Chinese subpopulation. CONCLUSIONS/INTERPRETATION: Oral semaglutide resulted in significantly greater reductions in HbA1c across all doses and in significant body weight reductions for the 7 mg and 14 mg doses when compared with placebo in predominantly Chinese participants with type 2 diabetes insufficiently controlled by diet and exercise alone. Oral semaglutide was generally well tolerated, with a safety profile consistent with that seen in the global PIONEER trials. TRIAL REGISTRATION: ClinicalTrials.gov NCT04109547. FUNDING: Novo Nordisk A/S.
引用
- Wang W, Bain SC, Bian F, et al. Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial. Diabetologia. 2024. PMID: 38985162. doi:10.1007/s00125-024-06142-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。